Bibliography
- JEMAL A, WARD E, HAO Y, THUN M: Trends in the leading causes of death in the United States, 1970-2002. JAMA (2005) 294:1255-1259.
- BARR ELM, ZIMMET PZ, WELBORN TA et al.: Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance. The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation (2007) 116(2):151-157.
- VASAN RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation (2006) 113:2335-2362.
- Annual Review of Genomics and Human Genetics (2006) 7.
- NICHOLLS SJ, SIPAHI I, SCHOENHAGEN P et al.: ACTIVATE Investigators. Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. Am. Heart J. (2006) 152:67-74.
- TARDIF JC, GRÉGOIRE J, L'ALLIER PL et al.: Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Effects of the acyl-coenzyme A:cholesterol acyl-transferase inhibitor avasimibe on human atherosclerotic lesions. Circulation (2004) 110:3372-3377.
- KASTELEIN JJP, VAN LEUVEN SI, BURGESS L et al.: RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Eng. J. Med. (2007) 356:1620-1630.
- NISSEN SE, TARDIF J-C, NICHOLLS SJ et al.: ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Eng. J. Med. (2007) 356:1304-1316.
- AGERHOLM-LARSEN B, NORDESTGAARD BG, STEFFENSEN R, JENSEN G, TYBJAERG-HANSEN A: Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in cholesteryl ester transfer protein gene. Circulation (2000) 101:1907-1912.
- CURB JD, ABBOTT RD, RODRIGUZ BL et al.: A prospective study of HDL-c and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res. (2004) 45:948-953.
- TALL AR: CETP inhibitors to increase HDL cholesterol levels. N. Engl. J. Med. (2007) 356:1364-1366.
- TALL AR, YVAN-CHARET L, WANG N: The failure of torcetrapib. Was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. (2007) 27:257-260.
- LEWIS GF, RADER DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. (2005) 96:1221-1232.